Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

Main Inclusion Criteria: * Subject (or parent/guardian) willing and able to sign an informed consent * Age 8-25 (inclusive) years * Recently diagnosed with T1DM * Basal C-peptide ≥ 0.2 pmol/mL * Positive for at least one diabetes-related autoantibody * Ability and consent to comply with completion of patient diary * No significant abnormalities in serum hematology, serum chemistry * No significant abnormalities in urinalysis * No significant abnormalities in ECG * For women of child bearing potential, non-pregnant, non-lactating female patients Main Exclusion Criteria: * IgA deficient subjects * Subjects who have received an active/ live virus vaccine within 4 weeks of the screening date * Subjects who have received treatment with corticosteroid medication within 2 months prior to screening or any immunosuppressant or cytostatic agent within 6 months prior to screening * Individuals with a history of severe immediate hypersensitivity reactions, including anaphylaxis, to plasma products * Clinically significant intercurrent illnesses * Pregnant or lactating women * Current use of any medication known to influence glucose tolerance * Current or prior (within the last 60 days prior to screening visit) use of metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors or amylin.